Resistance patterns of Pseudomonas aeruginosa isolated from HIV and non-HIV patients with lower respiratory tract infections.
The increase in occurrence of infections due to opportunistic
gram-negative bacilli in patients with impaired host defences emphasizes
the need for information on the antibiotic susceptibility of the
organisms that infects such patients. Pseudomonas aeruginosa are
becoming increasingly resistant to antimicrobial agents, and serious
infections caused by these organisms often require immediate attention
as they cause treatment failures. In vitro antimicrobial susceptibility
data are required for successful therapy because acquired resistance to
such antimicrobials as [beta]-lactams, fluoroquinolones and
aminoglycosides is so prevalent in P. aeruginosa. The study was carried
out in Chennai during the period May 2007 and March 2009. 69 isolates of
Pseudomonas were isolated from HIV and 24 isolates were isolated from
Non-HIV populations with lower respiratory tract infections. The
antibiotic susceptibility pattern of all the isolates was studied for 12
antibiotics to find the multi drug resistant (MDR) isolates for which
the minimum inhibitory concentration (MIC) were studied according to
KEY WORDS: Antibiotic resistance; P. Aeruginosa; MDR; HIV; Lower respiratory tract infection; MIC
Beta lactamases (Health aspects)
Beta lactamases (Research)
Drug resistance in microorganisms (Research)
Pseudomonas aeruginosa infections (Risk factors)
Pseudomonas aeruginosa infections (Care and treatment)
Pseudomonas aeruginosa infections (Research)
|Publication:||Name: Internet Journal of Medical Update Publisher: Dr. Arun Kumar Agnihotri Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 Dr. Arun Kumar Agnihotri ISSN: 1694-0423|
|Issue:||Date: Jan, 2012 Source Volume: 7 Source Issue: 1|
|Topic:||Event Code: 310 Science & research|
|Geographic:||Geographic Scope: India Geographic Code: 9INDI India|
A natural consequence of infectious agent is the antimicrobial resistance which occurs by adaptation of antimicrobials due to exposure in medicine used in farms and households (1-4).The effectiveness of the existing antimicrobials have declined which become difficult and expensive to treat the infection. (5-6). Pseudomonas aeruginosa have emerged as an opportunistic multidrug resistant pathogens which is a growing problem worldwide (7,8).
Lung infections caused by P. aeruginosa are limited to patients who are immunocompromised, or who have defective mucociliary clearance, previous epithelial injury or foreign body placement. Given its ubiquitous presence in our environment and pathogenic potential, it is clear that a normally functioning host defence is very well adapted to prevent P. aeruginosa infection. Despite this, P. aeruginosa infections can be devastating in the hospitalized or sick. Understanding the failures of the host defence in these patients will help us understand how P. aeruginosa is converted from a common environmental exposure to a deadly pathogen (9).
Pseudomonas infection remains one of the untreatable and uncontrollable infection of the hospitals. Clinically it has been shown that P. aeruginosa has the capacity to develop resistance rapidly during the course of antimicrobial therapy by several mechanisms (10-13). Therefore, sequential accumulation of resistance may result in emergence of multidrug resistance in P. aeruginosa. Factors influencing the emergence and spread of acquired resistance in P. aeruginosa include inadequate and overuse of antimicrobials (14).
The steady rise in adaptive and mutational resistance is increasingly impacting on therapeutic success and new antimicrobial therapeutic options are needed for resistant strains, some of which have developed resistance to virtually every type of antibiotic and have thus become hospital 'superbugs' (15). So this study was undertaken in order to assess the current level of susceptibility of widely used antipseudomonal antibiotics against P. aeruginosa.
Sixty-nine consecutive, Pseudomonas spp. isolates were collected between May 2007 and March 2009 from sputum samples from HIV patients was collected from Government hospital of thoracic medicine, Tambaram sanatorium, Chennai. Sputum samples from Non-HIV patients were collected from Government Stanley hospital, Chennai and Dr. Kamashi Memorial hospital, Chennai. All isolates were identified according to standard protocol of CLSI 2009. All cultures were incubated at 37[degrees]C for 24-48 h for isolation of Pseudomonas spp. Of these isolates, 45 were from HIV and 24 from non-HIV patients. The study was approved by the institutional ethical committee and informed consent was obtained from patients.
Antibiotic susceptibility testing-disc diffusion method
Antibiotic susceptibility testing was done by Kirby Bauer disc diffusion method as per Clinical Laboratory Standard Institute (CLSI) guidelines 2009. The following antipseudomonal antibiotics were used to screen for multidrug resistance among the isolates. The antibiotics included were piperacillin (100[micro]g), cefotaxime (30[micro]g), ceftazidime (30[micro]g), cefoperazone (75[micro]g), tobramycin (30[micro]g), ceftriaxone (30[micro]g), amikacin (30[micro]g), netilmicin (30[micro]g), ofloxacin (5[micro]g), ciprofloxacin (5[micro]g), imipenem (10[micro]g), mezlocillin (75[micro]g), azlocillin (75[micro]g), ticarcillin (75[micro]g).
MIC (Micro-Broth Dilution Method)
The MIC was done for the following antibiotics: ceftazidime, cefoperazone, cefotaxime (Orchid Pharmaceuticals Ltd), amikacin and ciprofloxacin (Hi Media laboratories ltd.). MICs were determined by micro broth dilution method as per CLSI guidelines using cation adjusted Mueller Hinton broth (CMHB, Difco) at pH 7.0. The antibiotics with various dilutions were prepared from the stock solutions and the inocula were prepared according to CLSI standards. Minimal inhibitory concentration (MIC) was visually read after 24 hrs of incubation at 37[degrees]C. MIC was defined as the lowest drug concentration resulting in 90% reduction in turbidity when compared to the drug free control. Minimum bactericidal concentration (MBC) was also done for further confirmation.
The final concentrations of the antibiotics ranged from 0.25[micro]g/ml to 256[micro]g/ml. P. aeruginosa ATCC 27853 was included as the quality control strain. Interpretive criteria for resistance to various antibiotics according to CLSI guidelines were as follows: ceftazidime ([greater than or equal to] 32[micro]g/ml), cefotaxime (64[micro]g/ml) cepoferazone ([greater than or equal to] 64[micro]g/ml), amikacin ([greater than or equal to] 64[micro]g/ml), and ciprofloxacin ([greater than or equal to] 4[micro]g/ml).
A total of 71 respiratory isolates of pseudomonas spp. were isolated both from HIV and Non-HIV patients with lower respiratory tract infection over the period of May 2007-March 2009. Among the 71 isolates 44 were Pseudomonas aeruginosa 19 were Pseudomonas stutzeri, 8 were Pseudomonas putida 1 were Alcaligenes faecalis Out of 71/45 were from HIV population, 24 were from Non-HIV and 2 were environmental isolates. A standard strain of ATCC was used as control. All the 71 (22.76%) isolates were examined for the antibiotic sensitivity against 15 antipseudomonal antibiotics. Table 1 shows that among the 45 HIV isolate tested, 37 (82.2%) showed resistance to ceftazidime, 30/45 (66.7%) showed resistance for mezlocillin. Ceftriaxone and cefotaxime resistance was shown by 29/45(64.4%), resistance to cefoperazone was shown by 27/45 (60%), whereas 21/45 (46.7%) showed resistance to ticarcillin. 10/45 (22.2%) showed resistance to, ciprofloxacin and piperacillin. 9/46 (20%) showed resistance to amikacin and azlocillin. 7/45 (15.6%) isolates showed resistance towards tobramycin and ofloxacin, 5/45 (11.1%) showed resistance to netilmicin. All the 45 isolates showed 100% sensitivity to imipenem.
Table 2 shows that non HIV isolates showed highest resistance to cefotaxime and mezlocillin 21/24(87.5%), they showed intermediate resistance to ceftazidime and ticarcillin 18/24 (75%) followed by resistance to cefoperazone 16/24 (66.7%). Azlocillin and ceftriaxone showed 11/24 (45.8%) resistance. 8/24 (33.3%) isolates showed resistance to piperacillin, while 3/24 (12.5%) showed resistance to amikacin followed by 2/24 (8.3%) resistance towards ciprofloxacin and imipenem. The least resistance was observed for ofloxacin 1/24 (4.17%).
Minimum inhibitory concentration by micro broth dilution method (MIC): The MIC for the antibiotics was tested by micro broth dilution method according to CLSI guidelines 2008. Among HIV isolates tested, 37 isolates which showed resistance for ceftazidime were taken for MIC studies of third generation cephalosporin. 13 (35.13%) showed resistance in our MIC studies. Thirteen out of 30 isolates (35.13%) showed resistance for cefotaxime and 17 out of 27 isolates (62.96%) were resistant to cefoperazone. 4 (40%)isolates showing ciprofloxacin resistance and 1(11.11%) out of 9 strains showed resistance to amikacin. (Table 3)
In non HIV isolates, 2 out of 16 isolates (12.5%) tested showed resistance by MIC for cefoperazone, 100% sensitivity was seen for ciprofloxacin, 4 (19.04%) out of 21 isolates showed resistance by MIC in our study for cefotaxime. 16 out of 18 isolates (88.89%) showed resistance by MIC for ceftazidime. (Table 4)
As resistance among P. aeruginosa continues to increase globally, novel dosage strategies will be needed to retain the effectiveness of currently available antibiotics. Pseudomonas is inherently resistant to many antimicrobial Agents. The rate of strains with acquired resistance to ceftazidime has been estimated to range from 10% to 40% (16). Our rate of ceftazidime resistance was 35.13%.the development of antibiotic resistance is very common during the course of treatment. Our results demonstrate that half of our isolates are multiple resistant both in HIV and in non-HIV population. These data indicate that a high number of isolates probably have resistance due to impermeability or multi-drug efflux or a combination of multiple unrelated resistance mechanisms. Ciprofloxacin showed the highest in vitro antibacterial activity followed by amikacin among the non HIV population whereas in HIV population only amikacin showed the highest antibacterial activity than ciprofloxacin in our centre (11,17,18). These data indicate that a high number of isolates probably have resistance due to impermeability or multi-drug efflux or a combination of multiple unrelated resistance mechanisms.
Although comparison between studies is difficult since patient populations of centres and methods of studying differ, interestingly, we found a higher level of resistance to cephalosporin group by disc diffusion method followed by penicillin group. Aminoglycosides and fluoroquinolones showed the least resistance. Whereas in MIC we noticed that in HIV isolates ciprofloxacin resistance was high compared to non-HIV isolates, in HIV cefoperazone showed the highest resistance by MIC followed by cefotaxime and ceftazidime compared to non-HIV where it was seen for ceftazidime followed by cefotaxime and cefoperazone (19-22). The incidence of resistance is dependent on the patterns of antibiotic usage. Our findings suggest that imipenem, amikacin and ciprofloxacin may be of significant value for the treatment of severe infections caused by P. aeruginosa. Though resistance to imipenem has developed in our study we did not find any imipenem resistance both in HIV and Non-HIV isolates tested. So imipenem remains the drug of choice for treatment in most of the severe cases and may be more useful than [beta]-lactams for combined treatment.
The prevalence of ceftazidime resistance in our study was 35.13% compared to other studies. There is a higher level of resistance among the HIV population than non-HIV population which may be due to the varying usage of antibiotics to treat infections in immunocompromised hosts. Hence there is a need for periodic surveillance of antibiotic resistance patterns and efforts to decrease empirical antibiotic therapy.
(1.) Bloomfield SF. Significance of biocide usage and antimicrobial resistance in domiciliary environments. Symp Ser Soc Appl Microbiol. 2002;92 Suppl:144S-57S.
(2.) McEwen SA, Fedorka-Cray PJ. Antimicrobial use and resistance in animals. Clin Infect Dis. 2002 Jan;34(Suppl 3):S93-S106.
(3.) Vidaver AK. Uses of antimicrobials in plant agriculture. Clin Infect Dis. 2002 Jan;34 Suppl 3:S107-10.
(4.) Wise R, Soulsby EJ. Antibiotic resistance--an evolving problem. Vet Rec. 2002 Sep;151(13):371-2.
(5.) Moellering Jr RC. Antibiotic resistance: lessons for the future. Clin Infect Dis. 1998 Aug;27 Suppl 1:S135-40.
(6.) Mah MW, Memish ZA. Antibiotic resistance: an impending crisis. Saudi Med J. 2000 Dec;21(12):1125-9.
(7.) Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis. 2001 May;32 Suppl 2:S146-55.
(8.) Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003 Feb;289(7):885-8.
(9.) Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology. 2010 Oct;15(7):1037-56.
(10.) Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy. 1995 May-Jun;15(3):279-91.
(11.) Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998 Aug;27 suppl 1:S93-9.
(12.) Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999 Jun;43(6):1379-82.
(13.) Le Thomas I, Couetdic G, Clermont O, et al. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother. 2001 Oct;48(4):553-5.
(14.) Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 2005 Jul;11suppl 4:17-32.
(15.) Falagas ME, Bliziotis IA . Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007 Jun;29(6): 630-6.
(16.) Nordman P, Guibert M. Extended-spectrum beta-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother. 1998 Aug;42(2):128-31.
(17.) Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002 Mar;34(5):634-40.
(18.) Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother. 2000 Apr;45(4):433-6.
(19.) Bonfiglio G, Carciotto V, Russo G, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother. 1998 Feb;41(2):307-10.
(20.) Henwood CJ, Livermore DM, James D, et al. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother. 2001 Jun;47(6):789-99.
(21.) Cavallo JD, Fabre R, Leblanc F, et al. Antibiotic susceptibility and mechanisms of [beta]-lactam resistance in 1310 strains of Pseudomonas aeruginosa: a French multicentre study (1996). J Antimicrob Chemother. 2000 Jul;46(1):133-6.
(22.) Bouza E, Garcia-Garrote F, Cercenado E, et al. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother. 1999 Apr;43(4):981-2.
Anitha Chandrahausan ([PSI]) * MSc, Padma Krishnan * PhD, Rajasekharan Sikhamani ** MD and Pushkala Murugavel *** MD
* Department of Microbiology (faculty of Medicine), Dr. ALM PGIBMS, University of Madras, Taramani, Chennai, India
** Government Hospital of Thoracic Medicine, Tambaram Sanatorium, Tambaram, Chennai, India
*** Dr. Kamashi Memorial Hospital Pallikaranai, Chennai, India
(Received 10 February 2011 and accepted 23 March 2011)
([PSI]) Correspondence at: Department of Microbiology, Meenakshi Medical College and Research institute, Enathur, Kanchipuram-631552, India; Mobile: 09840581510; Email: firstname.lastname@example.org
Table 1: Resistance pattern exhibited by Pseudomonas spp. among HIV patients to various antibiotics Number of strains resistant to Antibiotics group Antibiotics in [micro]g antibiotics (%) Carbapenems Imipenem (10 [micro]g) 0 (0) Cephalosporin Ceftazidime (30 [micro]g) 37 (82.2) Cefotaxime (30 [micro]g) 29 (64.4) Cefoperazone (75 [micro]g) 27 (60.0) Ceftriaxone (30 [micro]g) 29 (64.4) Aminoglycosides Amikacin (30 [micro]g) 9 (20.0) Tobramycin (30 [micro]g) 7 (15.6) Netilmicin (30 [micro]g) 5 (11.1) Fluoroquinolones Ofloxacin (5 [micro]g) 7 (15.6) Ciprofloxacin (5 [micro]g) 10 (22.2) Penicillin group Piperacillin (100 [micro]g) 10 (22.2) Mezlocillin (75 [micro]g) 30 (66.7) Azlocillin (75 [micro]g) 9 (20.0) Ticarcillin (75 [micro]g) 21 (46.7) Table 2: Resistance pattern exhibited by Pseudomonas spp. among Non-HIV patients to various antibiotics Number of strains resistant to Antibiotics group Antibiotics in [micro]g antibiotics (%) Carbapenems Imipenem (10 [micro]g) 2 (8.3) Cephalosporin Ceftazidime (30 [micro]g) 18 (75.0) Cefotaxime (30 [micro]g) 21 (87.5) Cefoperazone (75 [micro]g) 16 (66.7) Ceftriaxone (30 [micro]g) 11 (45.83) Aminoglycosides Amikacin (30 [micro]g) 3 (12.5) Tobramycin (30 [micro]g) 4 (16.7) Netilmicin (30 [micro]g) 4 (16.7) Fluoroquinolones Ofloxacin (5 [micro]g) 1 (4.2) Ciprofloxacin (5 [micro]g) 2 (8.3) Penicillin group Piperacillin (100 [micro]g) 8 (33.3) Mezlocillin (75 [micro]g) 21 (87.5) Azlocillin (75 [micro]g) 11 (45.8) Ticarcillin (75 [micro]g) 18 (75) Table 3: MIC for HIV isolates MIC Break points Antibiotics S I R S I R Ceftazidime 21 3 13 [less than or 16 >32 (N = 37) equal to] 8 Cefotaxime 4 12 13 8 1632 64 (N = 29) Cefoperazone 9 1 17 16 32 [greater than (N = 27) or equal to] 64 Ciprofloxacin -- 7 4 [less than or 2 [greater than (N = 10) equal to] 1 or equal to] 4 Amikacin 9 -- -- [less than or 32 [greater than (N = 9) equal to] 16 or equal to] 64 Table 4: MIC for Non-HIV isolates MIC Break points Antibiotics S I R S I R Ceftazidime 2 -- 16 [less than or 16 >32 (N = 18) equal to] 8 Cefotaxime 10 17 4 8 1632 64 (N = 21) Cefoperazone 13 1 2 16 32 [greater than (N = 16) or equal to] 64 Ciprofloxacin 1 1 -- [less than or 2 [greater than (N = 2) equal to] 1 or equal to] 4 Amikacin 3 -- -- [less than or 32 [greater than (N = 3) equal to] 16 or equal to] 64
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|